en · de · es · fr · pt
semaglutide-notes.peptides1004.com › News › Background And Molecular Profile — Practical Notes

Background And Molecular Profile — Practical Notes

By Editorial Desk · published 2026-04-05 · last reviewed 2026-04-29 · News

GLP-1 analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-04-29. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Molecular Profile

Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.

Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题,即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟,主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库,使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发,属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物,其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代,使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸,进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链,该侧链赋予分子与血浆白蛋白结合的能力。

该分子作为 GLP-1 受体的选择性激动剂发挥作用,受体属于 B 类 G 蛋白偶联受体家族,激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞,信号促进葡萄糖依赖性的胰岛素释放,血糖偏低时该作用明显减弱。在胰岛 α 细胞,胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达,相应信号参与食欲调节以及胃排空速率的降低。

Semaglutide at a glance

PropertyValueNotes
Molecular formula (free base)C187H291N45O59Approximate; salt and hydrate forms differ
Molecular weight~4113.6 DaVaries with counterion and hydration
AppearanceWhite to off-white powderLyophilized research material
Solubility classFreely soluble in waterAs formulated; native peptide less stable near neutral pH
Typical storage2 to 8 degrees CelsiusProtect from light; avoid repeated freeze-thaw

Semaglutide Structure and Receptor Mechanism

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.

Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.

Related pages on this site

Handling, Storage, And Analytical Checks

Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.

Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.

Background and Drug Class

Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.

Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.

Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.

Background from the literature

The number of growers expanded from 7,600 to at least 40,000 over the same period. Besides growers, the coca networks employed numerous Bolivians, including carriers (zepeadores), manufacturers of coca paste and cocaine, security personnel, and a large variety of other positions. The unparalleled revenues made the risk worthwhile for many. Government efforts to eradicate the expansion of coca cultivation in Bolivia began in 1983, when Bolivia committed itself to a five-year program to reduce coca production and created the Coca Eradication Directorate (Dirección de la Reconversión de la Coca—Direco) under the Ministry of Agriculture, Campesino Affairs, and Livestock Affairs. Bolivia's National Directorate for the Control of Dangerous Substances (Dirección Nacional para el Control de Substancias Peligrosas—DNCSP) was able to eradicate several thousand hectares of coca. These efforts put only a small dent in the coca industry and were highly controversial among thousands of peasants. Under the joint agreement signed by the United States and Bolivia in 1987, which created the DNCSP, Bolivia allocated US$72.2 million for the 1988 to 1991 period to eradication programs, including a wide-ranging rural development program for the Chapare region. The program was aided by an 88 percent drop in the local price of coca caused by the fall in cocaine prices in the United States. The economics of eradication were particularly frustrating. As more coca was destroyed, the local price increased, making it more attractive to other growers.

=== Chemical laboratories === Laboratory glassware such as beakers and reagent bottles Weighing scale Laboratory scissor jack Fume hoods Reagents Analytical devices, such as: High-performance liquid chromatography spectrophotometers Liquid chromatography–mass spectrometry

=== YAFMS === Yet Another Format for Mass Spectrometry (YAFMS) is a proposed format that saves data in four-table, relational, serverless database schemata, with data extraction and appending being exercised via SQL queries.

== Chemistry == Flmodafinil is a racemic mixture of (S)-(+)- and (R)-(–)-enantiomers. The (S)-(+) enantiomer has been referred to as JBG1-048 and the (R)-(–) enantiomer has been referred to as JBG1-049.

Sources: en.wikipedia.org

Reference notes

=== Dental === Silanization is often used to treat ceramics used for dental restorations and repairs. Applying silane coupling agents after grit blasting the ceramic material has been shown to produce durable resin bonding. Additionally, for titanium and other metal implant features in wires and crowns, application of silane coupling agents followed by resin composite cement has produced durable bonding in a clinical application. While silane coupling agents are widely used in dental practices, they are subject to bond degradation due to the environment of the oral cavity, weakening the adhesion between the surfaces that they are used to connect.

== Techniques in genome sequencing for pseudouridine == Pseudouridine can be identified through a multitude of different techniques. A common technique to identify modifications in RNA and DNA is Liquid Chromatography with Mass Spectrometry or LC-MS. Mass spectrometry separates molecules by the mass and charge. While uridine and pseudouridine have the same mass, they have different charges. Liquid chromatography works by retention time, which has to do with leaving the column. A chemical way to identify pseudouridine uses a compound called CMC or N-cyclohexyl-N′-β-(4-methylmorpholinium) ethylcarbodiimide to specifically label and distinguish uridine from pseudouridine. CMC will bond both with pseudouridine and uridine, but holds tighter to the former, because of the third nitrogen able to form hydrogen bond. CMC bound to pseudouridine can then be imaged by tagging a signaling molecule. This method is still being worked on to become high-throughput. An improved technique, 2-bromoacrylamide-assisted cyclization sequencing, enables Ψ-to-C transitions, for quantitative profiling of Ψ at single-base resolution.

Cockrum incorporated Kane's alteration into his artwork for the story. At the time of his initial appearances, basic ideas about Wolverine's abilities and origins remained in development. While some sources indicate that Wein originally intended for Logan to be a mutated wolverine cub evolved to humanoid form by the High Evolutionary, Wein has denied this, suggesting that this may have been Cockrum's idea. In an article about the evolution of Wolverine included in Incredible Hulk and Wolverine (1986), a reprint of The Incredible Hulk #180–181, Cockrum confirmed that he considered having the High Evolutionary play a vital role in making Wolverine a human. In Wein's original conception, Wolverine was a young adult, and his claws were retractable and part of his gloves, with both made of adamantium. Romita said that he always envisioned the claws as retractable, explaining: "When I make a design, I want it to be practical and functional. I thought, 'If a man has claws like that, how does he scratch his nose or tie his shoelaces?'" Wein recollects that Cockrum first suggested that the claws were installed in Wolverine's forearms. Romita established Wolverine's short stature, deciding that he would be 5 feet, 3 inches (1.6 meters), reflecting the small size of wolverines.

Sources: en.wikipedia.org

Reference notes

== Role of crotonyl-CoA in transcription == Post-translational modification of histones either by acetylation or crotonylation is important for the active transcription of genes. Histone crotonylation is regulated by the concentration of crotonyl-CoA which can change based on environmental cell conditions or genetic factors.

==== Benign soft tissue neoplasms ==== Peripheral nerve sheath tumours: These most commonly are traumatic neuromas, a reactive response to trauma, neurilemmoma and neurofibroma which are large growing painless tumours usually found on the tongue. Neurofibroma may occur as a benign solitary lesion but can present as multiple lesions associated with (Von Reckllinghausen's Disease) neurofibromatosis. They can be preceded by café au lait pigmentation spots on the skin, and as they grow can become very disfiguring. Malignant change can occur in neurofibromatosis but very rarely in single lesion presentation. Mucosal neuromas can be associated with other conditions such as multiple endocrine neoplasia (MEN) syndrome and may precede thyroid cancer. Lipoma and fibrolipoma: These are tumours of adipose tissue, or fat, giving them a yellow appearance which varies according to fat content. They are usually soft, mobile, slow growing painless and occur mostly in middle age or the elderly. Granular cell tumour: These are also tumours arising from neural cells, though it was incorrectly thought to arise from muscle cells and therefore previously called granular cell myoblastoma. It also is slow growing large painless and occurs mostly in the tongue. Congenital epulis: These are also known as congenital granular cell tumours (but not related to granular cell tumours), and occur mostly on the upper gum, the maxillary alveolar ridge, of newborns, predominantly females. Rarely, they occur elsewhere, usually the tongue. They are usually self-resolving.

{\displaystyle {\begin{array}{rl}{\ce {H2A <=> HA^- + H+}}:&K_{1}={\frac {{\ce {[HA-] [H+]}}}{{\ce {[H2A]}}}}\\{\ce {HA- <=> A^2- + H+}}:&K_{2}={\frac {{\ce {[A^{2-}] [H+]}}}{{\ce {[HA-]}}}}\end{array}}}

Aspartic acid, for example, possesses one protonated amine and two deprotonated carboxyl groups, for a net charge of −1 at physiological pH. Fatty acids and fatty acid derivatives are another group of carboxylic acids that play a significant role in biology. These contain long hydrocarbon chains and a carboxylic acid group on one end. The cell membrane of nearly all organisms is primarily made up of a phospholipid bilayer, a micelle of hydrophobic fatty acid esters with polar, hydrophilic phosphate "head" groups. Membranes contain additional components, some of which can participate in acid–base reactions. In humans and many other animals, hydrochloric acid is a part of the gastric acid secreted within the stomach to help hydrolyze proteins and polysaccharides, as well as converting the inactive pro-enzyme, pepsinogen into the enzyme, pepsin. Some organisms produce acids for defense; for example, ants produce formic acid. Acid–base equilibrium plays a critical role in regulating mammalian breathing. Oxygen gas (O2) drives cellular respiration, the process by which animals release the chemical potential energy stored in food, producing carbon dioxide (CO2) as a byproduct. Oxygen and carbon dioxide are exchanged in the lungs, and the body responds to changing energy demands by adjusting the rate of ventilation. For example, during periods of exertion the body rapidly breaks down stored carbohydrates and fat, releasing CO2 into the blood stream. In aqueous solutions such as blood CO2 exists in equilibrium with carbonic acid and bicarbonate ion.

Sources: en.wikipedia.org

Frequently asked questions

What is the relationship between semaglutide and native GLP-1?

It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.

Does the oral form work the same way as the injectable form?

Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.

Is the peptide naturally present in the human body?

No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.

Semaglutide 与天然 GLP-1 的主要差别是什么?

差别集中在三处:第 8 位残基被非天然氨基酸取代,第 34 位换成精氨酸,第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率,侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。

Network